All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NRD135S.E1
Therapeutic Area: Neurology Product Name: NRD.E1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: GEM Global Yield
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 28, 2021
Details:
The proceeds from this financing will be used to progress the clinical development of Novaremed’s lead product, NRD135S.E1, an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy (PDPN).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2021
Details:
Addex intends to use the net proceeds from the global offering, mainly to advance development of its portfolio of proprietary drug candidates based on its allosteric modulator development capabilities. These include dipraglurant for use in Parkinson's disease and dystonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NRD135S.E1
Therapeutic Area: Neurology Product Name: NRD135S.E1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NOE-101
Therapeutic Area: Neurology Product Name: NOE-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 01, 2020
Details:
Financing will advance the development of four clinical-stage product candidates including lead product NOE-101. The product candidates will be developed in neurological indications with severe unmet need.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Semorinemab
Therapeutic Area: Neurology Product Name: RG6100
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
In a Phase 2 trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer’s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: JNJ-40411813
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NRD135S.E1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Details:
The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients with neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Temelimab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bryan, Garnier & Co
Deal Size: $19.3 million Upfront Cash: Undisclosed
Deal Type: Investment January 31, 2020
Details:
Successfully completing this private placement provides GeNeuro the means to complete the planned study of temelimab in multiple sclerosis patients with disability progression without relapses.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
